title: Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils.
abstract: OBJECTIVE
  To investigate the effectiveness of 4 d' anti-Helicobacter pylori therapy on the H pylori-infected Mongolian gerbils based on physiological and pathological changes.
  
  
  METHODS
  We used 6-wk-old male gerbils orally inoculated with H pylori (ATCC43504, 2X10(8) CFU/mL). Seven weeks after H pylori inoculation, the animals of study group received 4 d' anti-H pylori triple therapy (H pylori-eradicated group). Seven days later, all animals of the H pylori-eradicated and control groups (H pylori-infected and H pylori-uninfected groups) were sacrificed. We examined gastric mucosal lesions macroscopically, studied gastritis microscopically and determined the stomach weight ratio, myeloperoxidase (MPO) activity and prostaglandin (PG) E(2) level.
  
  
  RESULTS
  The results showed that both macroscopic and histological gastric damages were significantly less in H pylori-eradicated group than H pylori-infected group. Stomach weight ratio, MPO activity and PGE(2) levels were significantly higher in H pylori-infected group than those in the other two groups.
  
  
  CONCLUSIONS
  Four days' anti-H pylori therapy was effective in the improvement of H pylori-induced gastric lesions in Mongolian gerbils.
authors.affiliation: Department of Internal Medicine, Taipei Medical University Hospital, No. 252, Wu-Hsing Street, Taipei 110, Taiwan, China. chunchao@tmu.edu.tw
authors.forename: Chun-Chao
authors.initials: CC
authors.lastname: Chang
authors.forename: Sheng-Hsuan
authors.initials: SH
authors.lastname: Chen
authors.forename: Gi-Shih
authors.initials: GS
authors.lastname: Lien
authors.forename: Yuarn-Jang
authors.initials: YJ
authors.lastname: Lee
authors.forename: Horng-Yuan
authors.initials: HY
authors.lastname: Lou
authors.forename: Ching-Ruey
authors.initials: CR
authors.lastname: Hsieh
authors.forename: Chia-Lang
authors.initials: CL
authors.lastname: Fang
authors.forename: Shiann
authors.initials: S
authors.lastname: Pan
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D017291:Clarithromycin / Q000494:pharmacology; D004359:Drug Therapy, Combination; D005753:Gastric Mucosa / Q000473:pathology*; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D005849:Gerbillinae; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects*; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D013047:Specific Pathogen-Free Organisms
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole
references.citation: J Gastroenterol Hepatol. 1999 Nov;14(11):1062-9
references.pmid: 10574132
references.citation: Dig Dis Sci. 1999 Feb;44(2):257-65
references.pmid: 10063909
references.citation: Eur J Pharmacol. 2000 Oct 20;406(3):461-8
references.pmid: 11040354
references.citation: Lancet. 1983 Jun 4;1(8336):1273-5
references.pmid: 6134060
references.citation: N Engl J Med. 1993 Feb 4;328(5):308-12
references.pmid: 8419816
references.citation: Dig Dis Sci. 1998 Apr;43(4):754-65
references.pmid: 9558031
references.citation: Jpn J Cancer Res. 2000 Aug;91(8):769-73
references.pmid: 10965015
references.citation: JAMA. 1994 Jul 6;272(1):65-9
references.pmid: 8007082
references.citation: Gastroenterology. 1994 Dec;107(6):1746-50
references.pmid: 7958687
references.citation: J Clin Gastroenterol. 1998;27 Suppl 1:S141-3
references.pmid: 9872511
references.citation: J Gastroenterol. 1996 Oct;31(5):755-7
references.pmid: 8887049
references.citation: J Gastroenterol. 1998 Feb;33(1):14-7
references.pmid: 9497215
references.citation: Gastroenterology. 1988 Jan;94(1):33-40
references.pmid: 3335295
references.citation: IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241
references.pmid: 7715068
references.citation: N Engl J Med. 1991 Oct 17;325(16):1127-31
references.pmid: 1891020
references.citation: J Gastroenterol. 1996 Nov;31 Suppl 9:24-8
references.pmid: 8959513